MarketCap
Facebook
X
TelegramAnnual report 2022
added 07-25-2022
Taro Pharmaceutical Industries Ltd. Operating Cash Flow 2011-2026 | TARO
Annual Operating Cash Flow Taro Pharmaceutical Industries Ltd.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -159 M | 45.8 M | 272 M | 324 M | 324 M | 438 M | 395 M | - | 358 M | 249 M | - | 181 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 438 M | -159 M | 243 M |
Quarterly Operating Cash Flow Taro Pharmaceutical Industries Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 78.1 M | - | - | - | 24.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 78.1 M | 24.4 M | 51.2 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M |  USA |
 |
AbbVie
ABBV
|
19 B | $ 209.63 | -0.71 % | $ 371 B | USA |
 |
Verastem
VSTM
|
-138 M | $ 4.99 | -5.77 % | $ 346 M | USA |
 |
VistaGen Therapeutics
VTGN
|
-42.1 M | $ 0.57 | -5.85 % | $ 17.6 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-15.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Voyager Therapeutics
VYGR
|
-132 M | $ 3.96 | -4.24 % | $ 232 M | USA |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
-19.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Arena Pharmaceuticals
ARNA
|
-452 M | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
-9.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
-80.7 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
-235 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
Avid Bioservices
CDMO
|
11 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-46 M | $ 12.36 | -11.46 % | $ 1.88 B | USA |
 |
Wave Life Sciences Ltd.
WVE
|
-187 M | $ 6.39 | 3.06 % | $ 1.08 B |  Singapore |
 |
Xenetic Biosciences
XBIO
|
-2.29 M | $ 2.78 | -0.71 % | $ 4.73 M | USA |
 |
BeiGene, Ltd.
BGNE
|
1.13 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
XBiotech
XBIT
|
-39.9 M | $ 2.27 | -1.73 % | $ 69.2 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
-181 M | $ 54.44 | -1.96 % | $ 4.24 B | Canada |
 |
Xeris Pharmaceuticals
XERS
|
28.6 M | $ 5.41 | -2.87 % | $ 868 M | USA |
 |
X4 Pharmaceuticals
XFOR
|
-85.6 M | $ 4.07 | -5.57 % | $ 172 M | USA |
 |
Xencor
XNCR
|
-135 M | $ 11.4 | -7.43 % | $ 846 M | USA |
 |
XOMA Corporation
XOMA
|
2.87 M | $ 29.93 | -1.97 % | $ 362 M | USA |
 |
22nd Century Group
XXII
|
-7.72 M | $ 2.41 | -18.03 % | $ 444 K | USA |
 |
BioDelivery Sciences International
BDSI
|
41 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
-92.1 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-75.6 M | - | - | $ 3.74 B | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
-13 M | $ 1.06 | -2.75 % | $ 21.7 M | Israel |
 |
Enochian Biosciences
ENOB
|
-7.87 M | - | - | $ 40.5 M | USA |